Amid an already slow rollout, Biogen's Aduhelm could soon face price competition — report
Despite the snail-paced rollout of Biogen’s controversially approved Alzheimer’s treatment Aduhelm, CEO Michel Vounatsos insisted on the latest earnings call that he’s confident in the drug’s long-term sales potential, especially once a reimbursement decision is made for Medicare patients.
But soon enough, Medicare coverage may be the least of Biogen’s worries.
Companies like Roche and Eli Lilly are already lining up reviews for their own Alzheimer’s candidates. And even though Roche is still months out from a potential approval, the company says it’s planning on offering the drug at a steep discount to Aduhelm’s hefty $56,000 price tag — which helped stoke a tempest of controversy surrounding the unproven therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.